On August 27, 2023, Biolinerx Granted Hong Seng Technology An Exclusive, Royalty-Bearing, Sublicensable License For Motixafortide (BL-8040) To Develop And Commercialize Motixafortide In Asia - 8K
Portfolio Pulse from Benzinga Newsdesk
Biolinerx has granted Hong Seng Technology an exclusive, royalty-bearing, sublicensable license for Motixafortide (BL-8040) to develop and commercialize in Asia.
August 30, 2023 | 10:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biolinerx's licensing of Motixafortide to Hong Seng Technology could potentially increase its revenue through royalties.
The licensing deal allows Biolinerx to earn royalties from the sales of Motixafortide in Asia, which could potentially increase its revenue. This could make the company more attractive to investors, potentially leading to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100